Table 1.
Base-case deterministic pairwise cost-effectiveness results
| Treatment | Total | Incremental (vs. avelumab) | ICER (£) | ||||
|---|---|---|---|---|---|---|---|
| Costs (£) | LYs | QALYs | Costs (£) | LYs | QALYs | ||
| TE mMCC | |||||||
| Chemotherapy | 9834 | 0.41 | 0.30 | 78,395 | 3.74 | 2.30 | 34,113 |
| SC | 7584 | 0.41 | 0.31 | 80,646 | 3.74 | 2.29 | 35,274 |
| BSC | 7465 | 0.41 | 0.31 | 80,764 | 3.74 | 2.29 | 35,335 |
| Avelumab | 88,229 | 4.15 | 2.60 | ||||
| TN mMCC | |||||||
| Chemotherapy | 10,607 | 1.94 | 1.34 | 77,292 | 3.56 | 2.02 | 38,205 |
| SC | 8918 | 1.94 | 1.35 | 78,981 | 3.56 | 2.02 | 39,178 |
| BSC | 7229 | 1.94 | 1.36 | 80,669 | 3.56 | 2.01 | 40,158 |
| Avelumab | 87,899 | 5.50 | 3.37 | ||||
BSC best supportive care, ICER incremental cost-effectiveness ratio, LYs life-years, mMCC metastatic Merkel cell carcinoma, QALYs quality-adjusted life-years, SC standard care, TE treatment-experienced, TN treatment-naïve